We surveyed 152 physicians in the U.S. to gauge their opinions on Patient Support Program (PSPs) providers during the pandemic. Physicians surveyed include GPs, Hematologists, Medical Oncologists, Rheumatologists, Pulmonologists, Endocrinologists and Infectious Disease Specialists. Overall perceptions of PSPs compared to before the pandemic have generally improved – especially in terms of responsiveness and the expertise of individuals working on PSPs.
The main unmet needs at this time remain the range of service hours and the availability of nurses over the phone.
Within the specialties surveyed, AstraZeneca and Amgen are seen as having provided the best overall experience since COVID. In most cases, facilitation of financial support, staff quality and responsiveness usually explain why a given PSP is preferred over others.
About half of physicians cannot specifically identify a PSP that has been more innovative than others since the beginning of the pandemic. Among those that do, AstraZeneca is more commonly mentioned.
AstraZeneca and Lilly are particularly likely to be mentioned as having PSPs that have been helpful in supporting with paperwork and reducing administrative burden during the pandemic.
Biosimilar drug PSPs are seen as generally quite similar as PSPs for originator drugs. In the few cases where they are seen as inferior, it is mainly because of they do not have as many employees and offer a smaller range of services. We have created a downloadable and shareable infographic based on this research.
- Perceptions of overall improvement of pharma-sponsored PSPs.
- Changes in perceptions on specific PSP features.
- Which PSPs have performed better overall since the pandemic, which ones have been most innovative and supportive.